The rush on weight loss drugs has sent Danish drugmaker Novo Nordisk’s market value to new records as its share prices soared rapidly after Europe’s biggest company shared better-than-expected results in its latest earnings report. The firm behind weight loss drug Wegovy and diabetes drug Ozempic has reported that its sales increased by 31% and its net profit surged by 51% in 2023 compared to the previous year (both in Danish kroner). Growth was driven by Novo’s obesity care sales which jumped by 154% compared to the previous year. Sales skyrocket for weight-loss drug firm Novo NordiskNovo Nor…